Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $178.00 at Citigroup

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective reduced by Citigroup from $193.00 to $178.00 in a research note released on Wednesday morning, Benzinga reports. Citigroup currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on ASND. Morgan Stanley raised their price target on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an equal weight rating in a report on Thursday, May 16th. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a buy rating in a research note on Tuesday, August 13th. StockNews.com downgraded Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a report on Wednesday. Finally, Bank of America boosted their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $187.08.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $119.15 on Wednesday. The business has a fifty day moving average price of $134.38 and a 200 day moving average price of $138.07. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The stock has a market capitalization of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ASND. Gilbert & Cook Inc. increased its stake in shares of Ascendis Pharma A/S by 8.4% in the fourth quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock worth $357,000 after acquiring an additional 220 shares during the period. Jump Financial LLC acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth about $1,681,000. Massachusetts Financial Services Co. MA raised its stake in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after buying an additional 254,749 shares during the last quarter. First Turn Management LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $19,092,000. Finally, Quadrant Capital Group LLC boosted its position in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.